Article
Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Clinical oncology (Royal College of Radiologists (Great Britain)) - 1 Nov 2022
Suryavanshi M, Jaipuria J, Mattoo S, Dhandha S, Khatri M
Abstract excerpt
AIMS: Presently, three generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are approved against oncogene addicted EGFR-mutant non-small cell lung cancer (NSCLC). Patients with actionable EGFR mutations invariably develop resistance. This resistance can be intrinsic (primary) or acquired (secondary). MATERIALS AND METHODS: This was a retrospective study carried out between...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.